The melanoma market has seen an increase in developer attention following recent breakthroughs. The identification of the role of BRAF mutations has revolutionized the treatment of melanoma, but with drug resistance a problem there is an opportunity for developers to move into this market. Novel combination therapies and immunotherapies are now poised to compete with the current marketed drugs.
Features and benefits
* Analysis of marketed melanoma drugs – development history, key clinical trial data, and assessment of clinical and commercial attractiveness
* Analysis of marketed and pipeline drugs in comparison to current standard of care
* In-depth analysis of late-stage pipeline drugs – development overview, SWOT analysis, and assessment of clinical and commercial attractiveness
* Discussion and assessment of pipeline drugs’ ability to meet unmet needs in treatment of melanoma
Highlights
Yervoy and Zelboraf’s high costs have generated significant commercial reward, but have limited uptake of the drugs in more cost-conservative markets. However, where funded they remain the standard of care due to the lack of alternative treatments.
The combination of pipeline BRAF inhibitor dabrafenib and MEK inhibitor trametinib is thought to be the biggest threat to the current marketed therapies. The potential of this combination therapy to overcome resistance to BRAF inhibitor monotherapy could allow it to compete strongly in this setting and take market share from Zelboraf.
The limited treatment options in the adjuvant setting will allow the pipeline drugs targeting this patient population to face fewer barriers to market entry. There are currently two melanoma vaccines in development in this setting.
Your key questions answered
* Identify the market leaders in this competitive indication.
* Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy.
* Understand how pipeline drugs will be used with current therapies and how the market is accessed through less competitive treatment settings
Buy your copy of this report @
http://www.reportsnreports.com/reports/179867-product-profiles-melanoma-novel-combination-therapies-will-increase-competition-for-marketed-drugs.html
Table of contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
PRODUCT OVERVIEW
Key marketed and pipeline products
Datamonitor’s assessment summary
MARKETED PRODUCT PROFILES
Yervoy (ipilimumab; Bristol-Myers Squibb)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Zelboraf (vemurafenib; Roche/Daiichi Sankyo)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other drugs
DTIC-Dome (dacarbazine; Bayer) and generic dacarbazine
Temodar (temozolomide; Merck & Co.)
Interleukin-2
PIPELINE PRODUCT PROFILES
Dabrafenib (GSK-2118436; GlaxoSmithKline)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Trametinib (GSK-1120212; GlaxoSmithKline)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Abraxane (albumin-bound paclitaxel; Celgene)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Allovectin-7 (velimogene aliplasmid; Vical)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
MAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
OncoVEX GM-CSF (talimogene laherparepvec; Amgen)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
POL-103A (Polynoma/CK Life Sciences)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Masitinib (AB-1010; AB Science)
Drug overview
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
